The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Paclitaxel is one of the most widely used antineoplastic drugs in the clinic. Unfortunately, the occurrence of cellular resistance has limited its efficacy and application. The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major memb...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer Ther
Glavni autori: Zhang, Hui, Patel, Atish, Wang, Yi-Jun, Zhang, Yun-Kai, Kathawala, Rishil J., Qiu, Long-Hui, Patel, Bhargav A., Huang, Li-Hua, Shukla, Suneet, Yang, Dong-Hua, Ambudkar, Suresh V., Fu, Li-Wu, Chen, Zhe-Sheng
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830771/
https://ncbi.nlm.nih.gov/pubmed/28265007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0511
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items